Literature DB >> 15966965

Clozapine treatment of psychosis associated with velo-cardio-facial syndrome: benefits and risks.

S Gladston1, D J Clarke.   

Abstract

BACKGROUND: Clozapine is licensed for the treatment of psychotic illnesses resistant to other antipsychotic medications. Velo-cardio-facial syndrome (VCFS) is associated with a vulnerability to psychotic illness that may be resistant to treatment with conventional typical and atypical antipsychotics. PATIENTS AND METHODS: A 32-year-old man with intellectual disability (ID) and a long history of treatment-resistant psychosis was found to have VCFS. Treatment with typical antipsychotic drugs and with one atypical olanzapine produced no improvement.
RESULTS: Treatment with clozapine produced an improvement in psychotic symptoms and associated behavioural abnormalities, but caused hypersalivation, constipation and a seizure disorder. The latter led to two fractures, one requiring surgery. The addition of sodium valproate stopped seizures.
CONCLUSIONS: Clozapine may improve psychotic symptoms for people with ID associated with VCFS, but clinicians should be alert for potential adverse effects.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15966965     DOI: 10.1111/j.1365-2788.2005.00708.x

Source DB:  PubMed          Journal:  J Intellect Disabil Res        ISSN: 0964-2633


  11 in total

1.  Response to clozapine in psychosis associated with velo-cardio-facial syndrome.

Authors:  Adeeb Yacoub; Maria Aybar
Journal:  Psychiatry (Edgmont)       Date:  2007-05

2.  Velocardiofacial Syndrome-Associated Psychiatric Illness and Response to Aripiprazole: A Case Study.

Authors:  Richard R Brewington; Jessica A Hellings; Merlin G Butler
Journal:  Am J Psychiatry Resid J       Date:  2008-01

3.  Response to clozapine in a clinically identifiable subtype of schizophrenia.

Authors:  Nancy J Butcher; Wai Lun Alan Fung; Laura Fitzpatrick; Alina Guna; Danielle M Andrade; Anthony E Lang; Eva W C Chow; Anne S Bassett
Journal:  Br J Psychiatry       Date:  2015-03-05       Impact factor: 9.319

4.  Discordance in Diagnoses and Treatment of Psychiatric Disorders in Children and Adolescents with 22q11.2 Deletion Syndrome.

Authors:  Andrea S Young; Vandana Shashi; Kelly Schoch; Thomas Kwapil; Stephen R Hooper
Journal:  Asian J Psychiatr       Date:  2011-06-01

5.  Signal of Gastrointestinal Congenital Malformations with Antipsychotics After Minimising Competition Bias: A Disproportionality Analysis Using Data from Vigibase(®).

Authors:  François Montastruc; Francesco Salvo; Mickaël Arnaud; Bernard Bégaud; Antoine Pariente
Journal:  Drug Saf       Date:  2016-07       Impact factor: 5.606

6.  Case Report: Successful Use of the Combination of Electroconvulsive Therapy and Clozapine in Treating Treatment-Resistant Schizophrenia and Catatonia in an Adult with Intellectual Disability.

Authors:  Pushpal Desarkar; Daniel Blumberger; Zafiris Jeff Daskalakis
Journal:  J Autism Dev Disord       Date:  2018-10

7.  Clozapine-induced gastroesophageal rumination in 22q11.2 Deletion Syndrome. A case report on gastroesophageal side effects management without renouncing clozapine's effectiveness.

Authors:  Tommaso Accinni; Marianna Frascarelli; Francesco Ghezzi; Alessia Panzera; Antonino Buzzanca; Martina Fanella; Carlo Di Bonaventura; Luca Carlone; Nicoletta Girardi; Massimo Pasquini; Fabio Di Fabio
Journal:  Clin Case Rep       Date:  2021-05-24

Review 8.  Clozapine for psychotic disorders in adults with intellectual disabilities.

Authors:  Muhammad Ayub; Khalid Saeed; Tariq A Munshi; Farooq Naeem
Journal:  Cochrane Database Syst Rev       Date:  2015-09-23

9.  An interictal schizophrenia-like psychosis in an adult patient with 22q11.2 deletion syndrome.

Authors:  Yasutaka Tastuzawa; Kanako Sekikawa; Tetsufumi Suda; Hiroshi Matsumoto; Hiroyuki Otabe; Shigeaki Nonoyama; Aihide Yoshino
Journal:  Epilepsy Behav Case Rep       Date:  2015-04-06

10.  Clozapine-induced myocarditis in an adolescent male with DiGeorge Syndrome.

Authors:  Ann Marie Ruhe; Imran Qureshi; David Procaccini
Journal:  Ment Health Clin       Date:  2018-11-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.